After 1,881 posts and almost nine years, Science Life has a new home: The Forefront, a new science, health and wellness news and information website for the University of Chicago Medicine, the Biological Sciences Division and the Pritzker School of Medicine.
A new analysis of genital human papillomavirus (HPV) in men shows that infection with one HPV type strongly increases the risk of reinfection with the same type. In fact, men who are infected with the type responsible for most HPV-related cancers are 20 times more likely to be reinfected within one year. This increased risk […]
Ernst Lengyel, MD, PhD, discusses the link between obesity and cancer.
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help physicians make better treatment choices for patients with gastric and esophageal adenocarcinoma.
Chuan He, PhD, is one of three recipients of the 2017 Paul Marks Prize for Cancer Research recognizing promising investigators aged 45 or younger for their efforts in advancing cancer research.
The Chicago EYES on Cancer program will recruit students from underrepresented backgrounds and teachers from Chicago Public Schools for a two-year summer research apprenticeship.
The FDA approved a breakthrough cancer treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin lymphoma, that uses genetically engineered immune cells to target cancer.
With a $4.7 million grant from the National Cancer Institute, UChicago’s Globus and cancer researchers at UChicago Medicine will build new protected cancer research networks that enable collaborations while keeping sensitive health data secure and private.
Three UChicago researchers received awards from the NIH High-Risk, High-Reward Research program to support innovative approaches to tackle major challenges in biomedical research.
The focal HIFU treatment option lowers the risk of impotence and incontinence for patients by using high-frequency sound waves to target tumors.